What is Larad?
Larad operates at the intersection of advanced biotechnology and agricultural productivity, specializing in the development of virus-like-particle (VLP) vaccines and sophisticated diagnostic solutions. The company addresses critical disease challenges within food animal production, offering a comprehensive suite of products including vaccines, diagnostic antigens, and specialized testing services. Beyond its proprietary product line, Larad provides contract R&D services, acting as a strategic partner for industry stakeholders seeking to mitigate health risks in livestock. By focusing on high-efficacy VLP technology, the firm provides essential tools that enhance animal welfare and operational efficiency for agricultural producers globally.
How much funding has Larad raised?
Larad has raised a total of $45K across 1 funding round:
Debt
$45K
Debt (2021): $45K with participation from PPP
Key Investors in Larad
PPP
Public-Private Partnership
What's next for Larad?
With the recent infusion of capital, Larad is poised to scale its manufacturing capabilities and broaden its diagnostic service offerings. The company's strategic roadmap likely involves expanding its footprint in international markets where food security and animal health are increasingly prioritized. As the firm transitions through its current growth phase, the focus will remain on clinical validation of its pipeline and the commercialization of its diagnostic platforms. Investors and industry observers will be monitoring how Larad utilizes this financing to deepen its R&D pipeline and establish long-term partnerships with major agricultural conglomerates, ultimately aiming to set a new standard for disease prevention in the food animal sector.
See full Larad company page
